Cargando…

Gastric and gastroesophageal junction cancer: Risk factors and prophylactic treatments for prevention of peritoneal recurrence after curative intent surgery

AIM: Relapse after curative treatment for advanced gastric cancer, and especially peritoneal recurrence, is very common and has a dismal prognosis. The aim of this review is to summarize existing evidence regarding risk factors and prophylactic treatments intending to prevent peritoneal recurrence....

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Biying, Rouvelas, Ioannis, Nilsson, Magnus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271029/ https://www.ncbi.nlm.nih.gov/pubmed/35847435 http://dx.doi.org/10.1002/ags3.12565

Ejemplares similares

Presentation of gastroesophageal junction adenocarcinoma with synchronous metastases at the small intestine. Could treatment with curative intent be considered? A case report
por: Huang, Biying, et al.
Publicado: (2021)

Laparoscopic Gastric Wedge Resection and Prophylactic Antireflux Surgery for a Submucosal Tumor of Gastroesophageal Junction
por: Lee, Jeong Sun, et al.
Publicado: (2011)

Risk factors and patterns of recurrence after curative resection in Gastroesophageal Junction Adenocarcinoma
por: Batool, Sadaf, et al.
Publicado: (2019)

Evaluation of resection of the gastroesophageal junction and jejunal interposition (Merendino procedure) as a rescue procedure in patients with a failed redo antireflux procedure. A single-center experience
por: Analatos, Apostolos, et al.
Publicado: (2018)

Two decades of gastric and gastroesophageal junction cancer surgery
por: Plum, Patrick S., et al.
Publicado: (2023)

Extent of Serosal Changes Predicts Peritoneal Recurrence and Poor Prognosis After Curative Surgery for Gastric Cancer
por: Kang, Yue, et al.
Publicado: (2015)

ASO Author Reflections: The Impact of Minimally Invasive Surgery on the Completion Rate of the Perioperative Chemotherapy Protocol in Gastric Cancer
por: Tsekrekos, Andrianos, et al.
Publicado: (2023)

Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer
por: Paschold, Lisa, et al.
Publicado: (2022)

Feature Review Papers on Gastroesophageal Junction and Gastric Cancers
por: Gronnier, Caroline
Publicado: (2022)

Prophylactic and Curative Inoculations
Publicado: (1900)

On Prophylactic and Curative Syphilization
Publicado: (1853)

Role of Peritoneal Lavage Cytology and Prediction of Prognosis and Peritoneal Recurrence After Curative Surgery for Colorectal Cancer
por: Bae, Sung Joon, et al.
Publicado: (2014)

Surgery with curative intent for stage IV gastric cancer: Is it a reality of illusion?
por: Kodera, Yasuhiro
Publicado: (2018)

Prognostic value of peritoneal scar-like tissue in patients with peritoneal metastases of ovarian origin presenting for curative-intent cytoreductive surgery
por: El Asmar, Antoine, et al.
Publicado: (2023)

Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
por: Charalampakis, Nikolaos, et al.
Publicado: (2022)

Extent of lymphadenectomy has no impact on postoperative complications after gastric cancer surgery in Sweden
por: Kung, Chih-Han, et al.
Publicado: (2017)

Conventional Cytology Is Not Beneficial for Predicting Peritoneal Recurrence after Curative Surgery for Gastric Cancer: Results of a Prospective Clinical Study
por: Kang, Ki-Kwan, et al.
Publicado: (2014)

The CHOLEGAS study: multicentric randomized, blinded, controlled trial of gastrectomy plus prophylactic cholecystectomy versus gastrectomy only, in adults submitted to Gastric cancer surgery with curative intent
por: Farsi, Marco, et al.
Publicado: (2009)

Higher incidence of gastroesophageal reflux disease after gastric wedge resections of gastric submucosal tumors located close to the gastroesophageal junction
por: Ko, Seung Yeon, et al.
Publicado: (2014)

Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial
por: Senthil, Maheswari, et al.
Publicado: (2023)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
por: Pericay, Carles, et al.
Publicado: (2016)

Very early-onset peritoneal recurrence following curative total gastrectomy for Borrmann 4 gastric cancer
por: Kim, Dong Jin, et al.
Publicado: (2014)

Implementation of minimally invasive gastrectomy for gastric cancer in a western tertiary referral center
por: Tsekrekos, Andrianos, et al.
Publicado: (2020)

The Incidence of Free Peritoneal Tumor Cells before and after Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer
por: Strandby, Rune B., et al.
Publicado: (2020)

Shedding some light on the use of mesh in gastroesophageal junction surgery
por: Fei, L, et al.
Publicado: (2010)

Prognostic Value of Preoperative Serological Biomarkers in Patients Undergoing Curative-Intent Cytoreductive Surgery for Colorectal Cancer Peritoneal Metastases
por: El Asmar, Antoine, et al.
Publicado: (2022)

Relevance of Position and Movement of the Gastroesophageal Junction in Gastroesophageal Reflux Disease
por: Lee, Yeong Yeh
Publicado: (2013)

Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab
por: Sama, Shashank, et al.
Publicado: (2019)

VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study
por: Smyth, Elizabeth, et al.
Publicado: (2020)

“Sentinel lymph node imaging with sequential SPECT/CT lymphoscintigraphy before and after neoadjuvant chemoradiotherapy in patients with cancer of the oesophagus or gastro-oesophageal junction – a pilot study”
por: Gabrielson, Stefan, et al.
Publicado: (2018)

Survival times are similar among patients with peritoneal, hematogenous, and nodal recurrences after curative resections for gastric cancer
por: Sawaki, Koichi, et al.
Publicado: (2020)

Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers
por: Goff, Laura W., et al.
Publicado: (2014)

Use of volumetric laser endomicroscopy for dysplasia detection at the gastroesophageal junction and gastric cardia
por: Gupta, Nina, et al.
Publicado: (2017)

Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas
por: Nielsen, Sofie L., et al.
Publicado: (2017)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery
por: Fan, Biao, et al.
Publicado: (2021)

Impact of Laparoscopic Gastrectomy on the Completion Rate of the Perioperative Chemotherapy Regimen in Gastric Cancer: A Swedish Nationwide Study
por: Tsekrekos, Andrianos, et al.
Publicado: (2023)

Early Detection of Colorectal Cancer Recurrence in Patients Undergoing Surgery with Curative Intent: Current Status and Challenges
por: Young, Patrick. E., et al.
Publicado: (2014)

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
por: Fashoyin‐Aje, Lola, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_63vhbcr1q8050idre5ac39ofsf